Case Study: Launch Planning and Readiness
How program management and strategic alignment prepared a biopharma company for NDA submission and launch.
Case Study: Leveraging Payer Insights to Shape Market Access Strategies and Tactics
How payer research helped refine value messaging, pricing strategy, and evidence plans.
Case Study: Preparing and Executing a Comprehensive 340B Contract Pharmacy Strategy
How a pharmaceutical company built a compliant, scalable 340B contract pharmacy program.
Policy is the New Payer: Why Access Strategy Must Now Navigate HHS, MFN, and Tariffs Together
In the June 2025 Navigating Market Access with Magnolia webinar, experts from across the market access ecosystem came together to examine the forces reshaping how manufacturers plan for pricing, reimbursement, and access.
Building a Comprehensive Go-To-Market Strategy Through Stakeholder Ecosystem Mapping
A mid-size client was preparing for a product launch and needed assistance facilitating a successful go-to-market strategy. The company sought to identify and understand the entire stakeholder landscape and create short- and long-term stakeholder engagement strategies to meet the needs of their entire organization.
Using Real-world Data to Support Product Label Change
A mid-size pharmaceutical
company was interested in
obtaining real-world evidence
demonstrating the safety and
effectiveness of higher dosage
chemotherapy for a labeled
oncology indication.
Objection Handling: How Should Manufacturers Evolve to Meet the Clinical and Contracting Demands of Payers?
Navigating Market Access with Magnolia Summer 2024 Presentation.
Identifying the Market, Business and Reimbursement Potential for Cell Therapies
Magnolia was asked to assess which type of cell therapies and disease states offered the greatest potential for development, and also wanted to further understand the benefits of creating an autologous or allogeneic product.
Developing a Comprehensive Launch Plan
Magnolia was engaged as a payer agency of record for a mental health digital therapeutic. Although the company had experience launching drugs in the U.S. market, the novelty of the digital therapeutic space was challenging, and the company did not have experience in mental health, nor a comprehensive launch plan in place across channels.
Telling a Value Story
A biopharma company engaged Magnolia to develop a value story for an orphan-designated treatment for an auto-immune disorder that was in Phase III development. The company’s product had a novel mechanism of action in comparison to the existing agents in development and would be the first new agent for the disease in years.